<DOC>
	<DOCNO>NCT02333045</DOCNO>
	<brief_summary>This study seek understand immune cell cervical fluid blood genital tract HIV-negative healthy female volunteer see cell modify use combine anti-viral antiinflammatory drug call maraviroc , medicine use treatment HIV infection .</brief_summary>
	<brief_title>Characterization Modulation Mucosal Immunity HIV Prevention Women</brief_title>
	<detailed_description>In study , investigator seek understand immune cell cervical fluid HIV-negative healthy female volunteer , see cell modify use combine anti-viral antiinflammatory drug call maraviroc , medicine use treatment HIV infection . Maraviroc work prevent HIV enter human immune cell block protein outside cell call C-C chemokine receptor type 5 ( CCR5 ) receptor . When maraviroc bound protein , virus enter cell . The investigator think CCR5 antagonist could particularly good drug HIV pre-exposure prophylaxis ( PrEP ) could potentially dose way easier take current drug use PrEP . In order evaluate PrEP strategy , investigator first study immune cell blood genital tract HIV-negative healthy female volunteer course 3 month see cell change time affected factor age , menstrual cycle , genital infection . The amount maraviroc compare drug current drug use PrEP ( tenofovir/ emtricitabine ) blood genital tract HIV-negative healthy female volunteer , , give maraviroc versus tenofovir/ emtricitabine 7 day measure . We also study immune cell blood genital tract woman see maraviroc , tenofovir , emtricitabine effect cell would prevent become infected HIV .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Age 1844 year Must biologically female ( defined sex birth ) HIV negative woman least one follow risk factor past 5 year 1 . Injection drug use use crack , cocaine , heroin , methamphetamine 2 . Diagnosed sexually transmit infection 3 . Unprotected sex 3 men 4 . Having sex drug , money , shelter 5 . Sex know HIVpositive man 6 . Having partner meet precede criterion Normal menses ( within 2235 day interval ) least 3 cycle No history alcohol abuse , heart disease , liver disease , medical condition would interfere conduct study , opinion study investigator No history loop electrosurgical excision procedure ( LEEP ) , conization , cryosurgery Normal chemistry , liver function , complete blood count panel screen , include : 1 . Absolute neutrophil count ( ANC ) ≥ 750/mm3 2 . Hemoglobin ≥ 10.0 g/dL 3 . Platelet count ≥ 100,000/mm3 4 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ≤ 3 x Upper Limit Normal ( ULN ) 5 . Total bilirubin ≤ 2.5 x ULN 6 . Creatinine Clearance ( CrCl ) ≥ 60 mL/min estimate CockcroftGault equation Negative hepatitis B surface antigen ( HBsAg ) No sign symptoms orthostasis No sign symptoms vaginal infection genital ulcer disease screen untreated vaginal infection last 30 day Not receive concurrent medication interact MVC antiretrovirals ( tenofovir/ emtricitabine [ Truvada® ] ) purpose HIV prevention Willing use condom duration study abstain sexual intercourse 48 hour genital tract sample Male sex ( defined sex birth ) Pregnant breastfeed Current use systemic hormonal contraception Symptomatic vaginal infection genital ulcer disease screen treatment vaginal infection last two week Active malignancy participant undergoing evaluation and/or treatment Immunosuppressive medication ( i.e , systemic steroid ) Any surgery precede 2 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV-negative</keyword>
	<keyword>Women</keyword>
	<keyword>At-risk</keyword>
</DOC>